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Abstract
Background: Previous work has shown reduced expression levels of let-7 in lung tumors. But little is known about the
expression or mechanisms of let-7a in prostate cancer. In this study, we used in vitro and in vivo approaches to investigate
whether E2F2 and CCND2 are direct targets of let-7a, and if let-7a acts as a tumor suppressor in prostate cancer by down-
regulating E2F2 and CCND2.
Methodology/Principal: Findings Real-time RT-PCR demonstrated that decreased levels of let-7a are present in resected
prostate cancer samples and prostate cancer cell lines. Cellular proliferation was inhibited in PC3 cells and LNCaP cells after
transfection with let-7a. Cell cycle analysis showed that let-7a induced cell cycle arrest at the G1/S phase. A dual-luciferase
reporter assay demonstrated that the 39UTR of E2F2 and CCND2 were directly bound to let-7a and western blotting analysis
further indicated that let-7a down-regulated the expression of E2F2 and CCND2. Our xenograft models of prostate cancer
confirmed the capability of let-7a to inhibit prostate tumor development in vivo.
Conclusions/Significance: These findings help to unravel the anti-proliferative mechanisms of let-7a in prostate cancer. Let-
7a may also be novel therapeutic candidate for prostate cancer given its ability to induce cell-cycle arrest and inhibit cell
growth, especially in hormone-refractory prostate cancer.
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Introduction
MicroRNAs (miRNAs) are endogenous, noncoding small RNAs
20–25 nucleotides in length [1], which play an important regulatory
role through complimentary binding of the 39 untranslated regions
(UTRs) of target genes. Binding results in the degradation of the
target mRNA and inhibition of translation [2]. Many miRNAs are
associated with cancer, and are involved in cell development,
differentiation, proliferation, and cell death [3]. Many reports have
indicated that miRNAs can be useful for cancer diagnosis and
therapy [4]. let-7 was first identified in Caenorhabditis elegans [5]. It is
nearly undetectable in the embryonic stage of development, but
becomesmoreabundantinlaterstagesofdevelopment[6].Previous
work has shown reduced expression levels of let-7 in lung tumors
compared to normal lung tissue. let-7 slows cellular proliferation by
down-regulating the oncogenes RAS/c-MYC and HMGA-2 at the
translational level [7,8]. The same tumor suppressive functions have
also been reported for let-7 in colon cancer [9].
In silico analyses of potential let-7a targets (www.targetscan.org
andwww.microrna.org) reveal that both E2F2 and CCND2 are
possible targets of let-7a. E2F2 and CCND2 are cell-cycle
regulators and aberrant expression of them can lead to abnormal
cellular proliferation. Our preliminary experiments indicate that
protein levels of both E2F2 and CCND2 are up-regulated in the
PC3 prostate cancer cell line. Little is known about the expression
or mechanisms of let-7a in prostate cancer. In this study, we used
in vitro and in vivo approaches to investigate whether E2F2 and
CCND2 are direct targets of let-7a, and if let-7a acts as a tumor
suppressor in prostate cancer by down-regulating E2F2 and
CCND2.
Materials and Methods
Ethics Statement
All samples were obtained from patients who signed informed
consent approving the use of their tissues for research purposes
after operation. The clinic pathological factors of the 26 patient
were showed in Table S1. The use of human tissues in this study
was approved by the Institutional Review Board of the Fourth
Military Medical University and was in accordance with their
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10147guidelines(No 2008039085). All experiments involving animals
were conducted according to the Animal Welfare Act and
approved by Animal Care and Use Committee of the Fourth
Military Medical University. (Approval number 200804052353).
Cell culture and tissue collection
Human prostate cancer cell lines LNCap, DU145, PC3, and
PrEC (prostate epithelial cells) and human embryonic kidney cells
HEK293A were obtained from American Type Culture Collec-
tion (ATCC, Manassas, VA, USA). Cells were cultured in RPMI-
1640 (Gibco) supplemented with 10% fetal-calf-serum and
penicillin (100 U/ml). Cultures were maintained under an
atmosphere containing 5% CO2 (Forma Scientific). Twenty-six
freshly resected prostate cancer specimens and their adjacent non-
tumorous specimens were collected from the Department of
Urology in Xi’jing Hospital. The specimens were immediately
frozen in liquid nitrogen and maintained there until use.
Plasmid construction and cell transfection
Let-7a was amplified and purified by miRNA isolation kit
(Invitrogen, Carlsbad, CA) according to manufacturer’s protocol.
PCR primers for let-7a were: 59-GAATTCTCACACAGGAAACCA-
GGA-39 (forward) and 59-CTGCAGTCAGGCATTTAAGTGACCG-39
(reverse). Let-7a PCR products were cloned into the EcoRI/PstI
cloning site of a pcDNA3 plasmid containing green fluorescent
protein (GFP) to form the plasmid pcDNA3-let-7a-GFP. Cell
transfection was performed with lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol. Briefly,
PC3 cells were plated in six well plates and grown without
antibiotics to 70–90% confluence. Each well received 6 mlo f
lipofectamine reagent containing 3 mg of plasmid DNA. Three
wells received pcDNA3-let-7a-GFP plasmid while the other wells
received the empty vector, pcDNA3-GFP. G418 (400 mg/ml) was
added to cells 24 h after transfection. Mixed clones were screened
and cultured for an additional 4 weeks. PC3 cells transfected with
let-7a were designated as PC3-let-7a-GFP, the negative control
(cells transfected with the empty vector) was designated as PC3-
GFP. PC3 cells were also transfected with 30 nM of synthetic let-
7a (mimics), and synthetic negative control miRNAs (NC). Lastly,
a synthetic let-7a-inhibitor sequence and synthetic let-7a-inhibitor
negative control (NC inhibitor). Sequences of synthetic hsa-let-7a,
negative control, hsa-let-7a inhibitor and inhibitor negative
control were showed in Text S1.
Total RNA extraction and real-time RT-PCR
For let-7a, Total RNA was extracted from samples using a
miRNeasy Mini Kit (Qiagen). cDNA was synthesized using
TaqMan MicroRNA Reverse Transcription Kit (Applied Biosys-
tems). Real-time RT-PCR was performed with TaqMan Micro-
RNA Assay kit (Applied Biosystems). The primer for let-7a was 59-
GAGGTAGTAGGTTGTATA-39. For E2F2 and CCND2, total
RNA extraction and real-time RT-PCR were performed using
SYBRH GreenER
TM Two-step kit (Invitrogen, Carlsbad, CA).
PCR primers for E2F2 were: 59-GAGCTCACTCAGACCCCAAG-39
(forward) and 59-AACAGGCTGAAGCCAAAAGA-39 (reverse). PCR
primers for CCND2 were: 59-AAGAATTCCTCCTCAATAGCCTG-
CAGCAGTA-39 (forward) and 59-GCGGGATATCGACCTGTGA-
GAATTCGAT-39 (reverse). All protocols were carried out accord-
ing to manufacturer protocols. The expression level of let7a was
normalized to RNU6B. The expression level of E2F2 and CCND2
were normalized to GAPDH. Real-time RT-PCR was performed
by using 7500 Real-time RT-PCR System (Applied Biosystems).
PCR was performed under the following conditions: 50uC for
2 min, 95uC for 10 min, followed by 50 cycles at 95uC for 15 s,
and 60uC for 1 min. Each sample was run in triplicate.
MTT Assay
PC3 cells and LNCaP cells transfected with either NC or let-7a
(mimics), or NC inhibitor and let-7a inhibitor were plated on 96-
well plates at 1610
4 cells/well. Viable cells were measured 1, 2, 3,
4, and 5 days after plating. After incubation with 3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT), the
cells were lysed in 150 ml of 100% dimethylsulfoxide (DMSO) and
UV-visible absorbance was read at 490 nm using the 96-well plate
reader. Each sample was run in triplicate.
Soft agar assay
Briefly, 2 ml of 0.5% agar was added to each well of a 12-well
plate. Detached PC3-let-7a-GFP and PC3-GFP cells were mixed
with the topagarose suspension (final concentration 0.3%), and
then the cells were layered onto the 0.5% agarose underlay. The
number of foci .100 mm were counted after 18 days. Each
experiment was performed in triplicate.
Cell cycle analysis
PC3 cells and LNCaP cells transfected with either NC or let-7a
(mimics), or NC inhibitor or let-7a inhibitor were harvested 72 h
after transfection, washed with cold phosphate buffered saline
(PBS), and fixed in 1ml of 70% ethanol. After overnight incubation
at 4uC in ethanol, cells were washed in PBS and suspended in
500 ml propidine iodide (PI) 30 min before flow cytometry.
Populations in G0-G1, S, and G2-M phase were measured by
flow cytometry (EPICS XL, Coulter, Miami FL) and the data were
analyzed by using Multicycle-DNA Cell Cycle Analyzed Software.
The measurement was performed in triplicate.
Dual-luciferase reporter assay
To investigate whether E2F2 and CCND2 expression were
regulated by let-7a, a dual-luciferase reporter assay was performed.
The 39-UTR of CCND2 and E2F2 were amplified by PCR
respectively. Amplification of CCND2 used the following primers:
59-GAATTCATGAGTTCTTCGTACTGG-39 (forward) and 59-GA-
TATCCCATCATGAT GAGGATAC-39 (reverse). PCR products
Figure 1. Let-7a expression in prostate cancer tissues and cells
measured by real-time RT-PCR. Real-time RT-PCR show that the
relative expression of let-7a in twenty-six prostate cancer samples, and
in prostate cancer cell lines LNCap, PC3, DU-145 is higher than that in
their adjacent non-cancerous specimens and the normal prostate
epithelial cell PrEC. Data are shown as percent of mean signals in tissues
and cells from three independent measurements. RNU6B was measured
in parallel and used to normalize the expression level of let-7a in each
experiment. Values represent means and error bars represent the SEM.
(* p,0.01, ** p,0.01; Mann-Whitney-U test).
doi:10.1371/journal.pone.0010147.g001
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mutated 39-UTR of CCND2 was synthesized after point
mutations were made in several bases within the binding sites of
these PCR products. Amplification of the 39-UTR of E2F2 used
the following primer sequences: 59-GAATTCCTCTTCGACTCC-
TACGAC-39 (forward) and 59-GATATCTGTGCTTCTT GGTA-
CGTCG-39 (reverse). The PCR products were 415 bp and
contained two binding sites for let-7a. Mutated 39-UTR of E2F2
were synthesized after several point mutations were made in the
binding sites PCR products. After restriction digestion, amplified
genes were cloned into the corresponding sites of a reconstructed
pGL3 expression vector. The pRL-TK control vector expressing
Renilla luciferase (Promega) was used for normalization of cell
number and transfection efficiency. Cotransfections of synthetic
let-7a sequence (mimics) and NC, or let-7a inhibitor and NC
inhibitor were also performed in human embryonic kidney cells
HEK293A by using lipofectamine 2000 (Invitrogen). Firefly and
Renilla luciferase activity was determined by Pikkagene Dual
Luciferase Assay System (Toyo-B-Net).
Western blotting analysis
The following antibodies were used for western blotting: mouse
anti-E2F2 (1:200 dilution, Santa Cruz Biotech); mouse anti-cdk4
and mouse anti-cyclin D2 (1:300 dilution; BD Biosciences, San
Jose, CA); mouse anti-k-RAS (1:300 dilution; Cell Signaling
Technology, Beverly, MA); rabbit anti-b-actin (1:4000 dilution,
Sigma). Twenty-five micrograms of prostate cancer specimens and
their adjacent non-tumorous specimens’ protein as well as PC3-let-
7a-GFP and PC3-GFP protein were electrophoresed in 10%
SDS–PAGE minigels and transferred onto Hybond C nitrocellu-
lose membranes (Amersham Life Science, Buckinghamshire, UK).
After incubating with primary antibodies at 4uC overnight, the
nitrocellulose membranes were washed three times with Tris-
Buffered Saline Tween-20 (TBST) and then incubated with
fluorecein isothiocyante (FITC)-conjugated, goat anti-mouse or
goat anti-rabbit IgG (1:500 dilution, Sigma) for 1 h at room
temperature. After washing with TBST, blots were visualized by
using the Odyssey Infrared Imaging system (LI-COR Bioscience,
Lincoln, Nebraska USA). Each assay was repeated three times.
Figure 2. Effect of let-7a on growth and proliferation of PC3 and LNCaP. (A) Relative expression of let-7a in PC3 cells transfected with
pcDNA3-GFP, pcDNA3-let-7a-GFP, NC, and let-7a (mimics). RNU6B was measured in parallel and used to normalize the expression level of let-7a in
each experiment. Values represent means from three separate experiments and error bars represent the SEM. (** p,0.01; Mann-Whitney-U test). (B)
PC3-let-7a-GFP and PC3-GFP cells were cultured in medium containing soft agar and incubated for 18 d. The number of foci .100 mm were counted.
Values represent means from three separate experiments and error bars represent the SEM. (* p,0.01; Mann-Whitney-U test). (C) Viability of PC3 cells
and LNCaP cells, which transfected with let-7a, NC or let-7a inhibitor, NC inhibitor was measured by MTT assays respectively. UV-visible absorbance
was measured at 490 nm. Values represent means from three separate experiments and error bars represent the SEM. (* p,0.05; Paired-sample T
test). (D) Analysis of cell cycle in PC3 cells after transfected with NC and let-7a (mimics) or NC inhibitor and let-7a inhibitor, as well as analysis of cell
cycle in LNCaP cells after transfected with NC and let-7a (mimics) or NC inhibitor and let-7a inhibitor. Values represent means from three separate
experiments and error bars represent the SEM. (* p,0.05, ** p,0.01; Mann-Whitney-U test).
doi:10.1371/journal.pone.0010147.g002
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Five nude mice were subcutaneously injected with ,1610
6
PC3-let-7a-GFP or PC3-GFP cells at a single site of the back. The
weight of the tumor and the weight of the mouse were measured at
the time of sacrifice (4 weeks after injection). Western blotting was
performed to investigate whether E2F2 and CCND2 were down-
regulated in nude-mouse xenograft model. Tumor suspensions
were treated with lysis buffer and western blotting was done
according to the procedures described above.
Statistical analysis
Differences between each group were determined by the T test
or Mann-Whitney U test using Statistical SPSS software package
(SPSS Inc, Chicago) (p,0.05 was regarded as significant).
Results
Let-7a is down regulated in resected prostate cancer
samples and in prostate cancer cells
Real-time RT-PCR revealed that the expression levels of let-7a
were decreased by ,43% in resected human prostate cancer
samples compared to the adjacent non-cancerous samples. The
prostate cancer cell lines LNCap expressed only ,70% as let-7a
than normal prostate epithelial cells PrEC. Additionally, the
amount of let-7a expression in PC3 cells and DU-145 were about
50% of that observed in PrEC. These results indicate that let-7a is
decreased in prostate cancer, including the androgen-independent
cancers PC3 (Fig. 1, * p,0.05; ** p,0.01).
Let-7a inhibits cell growth in vitro and induces cell cycle
arrest at the G0-G1 phase
After transfection, the expression level of let-7a in PC3-let-7a-
GFP was ,300% higher than in PC3-GFP by real-time RT-PCR;
A ten-fold increase in expression of let-7a was observed in PC3
cells transfected with let-7a (mimics) versus those transfected with
NC (Fig. 2A, p,0.01). This indicated that transfection was
appropriately performed. Colony formation analysis indicated that
the colonies formation ability of PC3-let-7a-GFP cells is ,40% less
than that of control cells (Fig. 2B, p,0.01). MTT growth curves
indicated that from the second day, the survival of let-7a
transfected PC3 cells and LNCaP cells are significantly less than
that of negative control, and the survival of let-7a inhibitor
Figure 3. Luciferase activity using wild-type and mutated CCND2 and E2F2 39UTR constructs. (A) Binding sites on E2F2 and CCND2 for
let-7a with the corresponding mutated E2F2 and CCND2 sequences. (B) Relative luciferase activity of human embryonic kidney cells HEK293A after
transfection with NC or let-7a (mimics) and then also co-transfected with pRL-TK control vector, or pGL3 expression vector containing either WT-
CCND2-39UTR or MUT-CCND2-39UTR or WT-E2F2-39UTR or MUT-E2F2-39UTR. (C) Relative luciferase activity of human embryonic kidney cells HEK293A
after transfection with NC inhibitor or let-7a inhibitor and also co-transfected with the pRL-TK control vector, or the pGL3 expression vector
containing either WT-CCND2-39UTR or WT-E2F2-39UTR. Values represent means from three separate experiments and error bars represent the SEM.
(** p,0.01; Mann-Whitney-U test).
doi:10.1371/journal.pone.0010147.g003
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that of NC inhibitor transfected cells (Fig. 2C, p,0.05). Flow
cytometry showed that the percentage of let-7a transfected PC3
cells and LNCaP cells in the G0-G1 phase was ,30% (PC3) and
16% (LNCaP) higher than that of negative control, which
paralleled with a ,50% (PC3) and 20% (LNCaP) decrease in
the S phase. the percentage of let-7a inhibitor transfected PC3 cells
and LNCaP cells in the G0-G1 phase was ,23% (PC3) and 19%
(LNCaP) less than that of NC inhibitor transfected cells, which
paralleled with a ,33% (PC3) and 25% (LNCaP) increase in the S
phase (Fig. 2D, * p,0.05; ** p,0.01). These data indicate that let-
7a inhibits PC3 proliferation by inducing cell-cycle arrest at G1/S
phase.
Let-7a targets 39UTR of E2F2 and CCND2
Figure 3A shows the sequences of the 39 UTRs of E2F2 and
CCND2 that represent the binding sites for let-7a. The
corresponding sequences of the mutated 39 UTRs of E2F2 and
CCND2 are shown as well. No reduction of luciferase activity was
observed in HEK293A cells transfected with let-7a (mimics) and
mutated CCND2 or E2F2. But greater than 30% reduction of
luciferase activity was observed with wild-type CCND2 and
,50% reduction of luciferase activity was observed with wild-type
E2F2 (Fig. 3B, **p,0.01). Compared to NC inhibitor, there is no
significant difference in luciferase activity when HEK293A cells
were transfected with the let-7a inhibitor and wild-type CCND2
or E2F2 (Fig. 3C). These data support that E2F2 and CCND2 are
direct targets of let-7a and endogenous let-7a in HEK293A has no
interference to our experience.
Let-7a inhibits expression of E2F2, CCND2
Real-time RT-PCR shows that mRNA relative expression of
E2F2 and CCND2 in prostate cancer tissues and in LNCaP, PC3,
and DU-145 cells are up-regulated compared with their adjacent
Figure 4. Effect of let-7a on expression of E2F2 and CCND2. (A) Real-time RT-PCR show that relative expression level of E2F2 in prostate
cancer tissues and in LNCaP, PC3, and DU-145 cells is much higher than in their adjacent non-cancerous specimens and PrEC cells (* p,0.05, **
p,0.01; Mann-Whitney-U test). (B) Real-time RT-PCR show that relative expression level of CCND2 in prostate cancer tissues and LNCaP, PC3, and DU-
145 cells is much higher than in their adjacent non-cancerous specimens and PrEC cells (* p,0.05; Mann-Whitney-U test). (C) Real-time RT-PCR show
that relative expression level of E2F2 in LNCaP and PC3 cells is less than in PrEC cells after transfected with let-7a (* p,0.05, ** p,0.01; Mann-
Whitney-U test). (D) Real-time RT-PCR show that relative expression level of CCND2 in LNCaP and PC3 cells is less than in PrEC cells after transfected
with let-7a (* p,0.05; Mann-Whitney-U test). All the values represent means from three separate experiments and error bars represent the SEM.
GAPDH was measured in parallel and used to normalize the expression levels of E2F2 and CCND2 in each experiment. (E) Western blotting show that
no change of CDK4 expression between prostate cancer tissues and their adjacent non-cancerous specimens, or between PC3-let-7a-GFP cells and
PC3-GFP cells. The expression levels of E2F2 and CCND2 is higher in prostate cancer tissues than in their adjacent non-cancerous specimens. After
transfected with let-7a, the expression levels of E2F2, CCND2, and k-ras decreased dramatically in PC3-let-7a-GFP cells compared with that in PC3-GFP
cells. b-actin was used the loading control.
doi:10.1371/journal.pone.0010147.g004
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p,0.01). But compared to PrEC, mRNA expression of E2F2 and
CCND2 are down-regulated after transfected with let-7a in PC3
and LNCaP cells (Fig. 4C, D, * p,0.05; ** p,0.01). Western
blotting results showed no change of CDK4 protein expression
between prostate cancer tissues and their adjacent non-tumorous
tissues or between PC3-let-7a-GFP cells and PC3-GFP cells, the
expression levels of E2F2, CCND2 increased in prostate cancer
tissues compared with their adjacent non-tumorous tissues, but the
expression levels of E2F2, CCND2, and k-ras decreased
dramatically in PC3-let-7a-GFP cells compared with that in
PC3-GFP cells (Fig. 4E). k-ras, a previously-defined molecular
target of let-7a[7] was used as a positive control for these
experiments. These data support that let-7a down-regulating the
mRNA expression of E2F2 and CCND2 and repress protein
translation of them.
Let-7a inhibits tumor growth in nude mice xenograft
model
Nude mice bearing PC3-let-7a-GFP or PC3-GFP xenografts
were sacrificed 4 weeks after innoculation. Tumors were excised
and measured (Fig. 5A). Western blotting showed that expression
levels of E2F2 and CCND2 decreased dramatically in PC3-let-7a-
GFP tumors compared with PC3-GFP tumors (Fig. 5B). The
weight of PC3-let-7a-GFP tumors was ,80% lighter than PC3-
GFP tumors (Fig. 5C, p,0.01). Furthermore, the ratio of tumor
weight/body weight in mice bearing PC3-let-7a-GFP tumors was
only ,6% of the ratio from mice bearing PC3-GFP tumors
(Fig. 5D, p,0.01), which provides strong evidence that let-7a can
inhibit tumor growth in vivo.
Discussion
The inability of a cell to regulate its growth and proliferation is a
distinctive feature of cancer. As critical molecules in cell-cycle
regulation, E2F proteins are downstream of growth-factor
signaling cascades. They influence cell growth and proliferation
through their ability to regulate genes involved in cell-cycle
progression [10,11]. E2F2 is a member of the E2F family of
transcription factors, and has been well-characterized as a
regulator of the G1-to-S-phase transition [12]. Previous reports
indicate that E2F2 has strong oncogenic capacity and can promote
cell-cycle progression. Cell lines transfected with E2F2 proliferate
at twice the rate of control cells [13]. For proper progression
through the cell cycle, phosphorylation activity of cyclin
dependent kinase (Cdk) is essential. CCNDs are expressed in the
early G1 phase and bind Cdk4 and Cdk6 [14]. The activation of
these kinases results in phosphorylation of other critical cell-cycle
regulators such as pRb. pRb then activates E2Fs and allows S-
phase entry. Accordingly, aberrant expression of CCND2 and
E2F2 will lead to abnormal cellular proliferation. Overexpression
of CCND2 was reported in ovarian granulose cell tumors, gastric
cancer and colon cancer [15–17]. Similarly, upregulation of E2F2
was found in astrocytomas of different grades [18].
miRNAs post-transcriptionally regulate gene expression by
binding to the 39UTR of target mRNAs. Binding leads to the
degradation of target mRNAs and reduced translation of target
Figure 5. Effect of let-7a on tumorigenicity in xenograft models. (A) Photograph of excised tumors 4 weeks after implantation. The upper
row shows tumors excised from mice injected with PC3-GFP cells. The lower are tumors excised from mice injected with PC3-let-7a-GFP cells. Of mice
injected with PC3-let-7a-GFP cells, no tumor was detected in one mouse and one mouse died 2 days after injection. (B) Western blotting showed that
the expression of E2F2 and CCND2 decreased dramatically in tumors excised from PC3-let-7a-GFP-tumor-bearin mice compared to those with PC3-
GFP tumors. b-actin was used as an internal control. (C) Tumor weight and (D) ratio of tumor weight/body weight were determined when mice were
sacrificed. Values represent means and error bars represent the SEM. (** p,0.01; Mann-Whitney-U test).
doi:10.1371/journal.pone.0010147.g005
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are downstream of direct targets and can lead to changes in global
protein expression profiles. Therefore, miRNAs potentially play a
critical role in the progression of human cancer. A great deal of
evidence supports that aberrant expression of miRNAs occurs in
diverse types of human cancer, and at different stages of cancer
progression [19,20]. let-7 has been reported to act as a tumor
suppressor in some cancer types, such as lung and colon
cancer[9,21–23] and that reduced expression levels of let-7 is
correlated with poor clinical prognosis [24].
Although this correlation between let-7 expression and disease is
strongest in lung tissue, where let-7 expression is high, our study
finds that let-7 causes cell cycle defects in prostate cancer cell line
as well. We found that let-7a expression level is down-regulated
dramatically in prostate cancer tissue and cells lines. Protein and
mRNA expression levels of E2F2 and CCND2 are down-regulated
in PC3 and LNCaP cells after transfection with let-7a. Our
xenograft models of prostate cancer also confirm our in vitro results
and show that let-7a has the ability to inhibit prostate tumor
development in vivo. Our dual-luciferase reporter assay verified
that E2F2 and CCND2 are direct targets of let-7a. Also, other
genes associated with cell-cycle regulation have been reported to
be repressed directly or indirectly by let-7. These include CDC34,
which promotes the degradation of cyclin dependent kinase (CDK)
inhibitor 1B and CCNA2, which promotes G1-S and G2-M phase
transitions [25]. Our founding expands the family of let-7 targets,
and the identifying the molecular pathways affected in cancer
could further reveal the mechanisms by which let-7a inhibits cell
division. Though much is still to be learned about the role of let-7a
in prostate cancer tumorigenesis, let-7a provides us a new way of
prostate cancer treatment via its ability to inducing cell cycle arrest
and inhibiting cell growth.
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